Chicharros USA - bolsa internacional

Tremendo, Framus... que una acción te suba como un 9000% en apenas unos días, no sé muy bien en qué estado debe dejarte...

Ya sé que son sueños y cábalas, pero por hacer una multiplicación: imagina tu inversión fuerte de NVAX en una de estas locuras: ¿unos 9 millones de dólares, con esos datos?

Lo estaba editando precisamente arriba.. es que no había leído todavía la prensa... Madre mía...

Espero que Eleuterio ya no las lleve, como creo... y que tampoco las lleve nadie aquí...

calla calla, solo de pensarlo se me nubla la vista ja,ja ... pero para que te pase eso tienes que estar como una puta cabra en un principio para comprar KBIO a 0,5 gastandote mucha pasta.

Of course... pero me encantaría saber cuántos locos que no sabemos han pillado esas KBIO bajas y han tenido la sangre fría de mantenerlas hasta ayer... Algo así te resuelve la vida...

Pero es que las KBIO todavía están a 20$!!!!!...yo no entiendo como la gente no las suelta ya si es que no lo han hecho todavía. En fin, a lo mejor me equivoco y se vuelven a ir a 40 pero hay que tenerlos cuadrados para entrar ahora ahí

Hoy las GSN hay que tenerlas un poco mas de respeto....empiezan en el PRE subiendo pero no es la alegria de ayer, puede ser una caza de lobos

Eso siempre... sólo cuando uno vende algo es cuando ya puedes respirar tranquilo... yo no hago cábalas, nunca lo he hecho, con ninguna acción, de si las veré hoy a 0.15, a 0.20, valdrán 1 dólar o se desplomarán...

Buenas tardes...
Imagino que esta new le sentará bien al valor...

CTIX

FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis

BEVERLY, MA--(Marketwired - November 25, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Brilacidin-OM, an oral rinse formulation of the Company's novel defensin-mimetic Brilacidin, for the prevention of oral mucositis. Oral mucositis, a common and often debilitating inflammation and ulceration that occurs in the mouth as a side-effect of certain cancer treatments, afflicts approximately 450,000 patients each year in the United States and can affect the course and outcome of cancer therapy. There are no FDA approved drugs for the prevention of oral mucositis.
In an ongoing Phase 2 trial, Brilacidin-OM is being evaluated for its safety and efficacy in preventing oral mucositis in patients undergoing chemoradiation for the treatment of head and neck cancer. Seven clinical sites and two satellite sites are currently enrolling patients in the trial, with additional sites expected to open enrollment in the coming weeks.
The FDA established the Fast Track Designation process to facilitate the development, and expedite the review of, drugs that have the potential to treat serious and life threatening conditions and fill an unmet medical need. Drugs developed under the Fast Track program are afforded increased access to the FDA and could qualify for other programs to expedite development, including priority review and accelerated approval.
"Hundreds of thousands of patients suffer from oral mucositis each year, including many of the approximately 60,000 patients diagnosed with head and neck cancer, with no drug available to help prevent it," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "We are very optimistic about our defensin-mimetic franchise given the strong antibacterial properties of Brilacidin-IV shown in clinical trials for ABSSSI and lab studies demonstrating the anti-inflammatory and anti-biofilm properties of Brilacidin-OM, which we hope to validate in the Phase 2 trial in oral mucositis patients. The Fast Track Designation provides us a greater opportunity to interact with the FDA and the possibility of other programs to assist in hastening the development of Brilacidin-OM. With the Orphan Drug Designation for drug Kevetrin to treat retinoblastoma, an FDA meeting being scheduled at the beginning of 2016 for our planned Phase 2 trial of Kevetrin for ovarian cancer, which is also being developed under an Orphan Drug Designation, and now this Fast Track Designation for Brilacidin-OM, it's been a solid month of developments with the FDA for our oncology pipeline."